logo

Repros Therapeutics Inc. (RPRX)



Trade RPRX now with
  Date
  Headline
5/7/2015 9:18:01 AM Repros Therapeutics Q1 Net Loss $8.5 Mln Or $0.35/shr Vs. Net Loss $8.8 Mln Or $0.38/shr Last Year
3/16/2015 9:16:21 AM Repros Therapeutics Q4 Loss Per Share $0.31 Vs Loss $0.32 Last Year
2/2/2015 9:19:25 AM Repros Therapeutics Says Electronically Submits New Drug Application To US FDA For Androxal
11/10/2014 9:06:21 AM Repros Therapeutics Q3 Loss Widens To $0.32 From $0.26 Last Year
10/21/2014 4:30:48 PM Repros Reports Results From Long-Term Study Of Androxal Exhibit Positive Safety Profile
9/26/2014 6:50:43 AM FDA Schedules Type B Pre-NDA Meeting With Repros
9/25/2014 8:24:06 PM Repros Reports Positive Top Line Results From Second Pivotal Study Of Androxal
9/19/2014 7:02:11 AM It's Time To Cross The T's...
8/11/2014 9:16:29 AM Repros Therapeutics Q2 Loss Per Share $0.38, Inline With Last Year
5/13/2014 10:18:09 AM Repros Says Fully Enrolls Second Head To Head Study Of Androxal Versus Topical Testosterone Gel
5/12/2014 9:17:16 AM Repros Therapeutics Q1 Loss/Shr $0.37 Vs. Loss $0.41 Last Year
4/30/2014 4:47:02 PM Repros Therapeutics Received FDA Guidance Regarding Primary Endpoints For Two Studies, ZA-304 And ZA-305